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1. Introduction
Diabetes mellitus (DM) is a group of metabolic diseases characterized with inappropriate
hyperglycemia due to either a deficiency of insulin secretion or a combination of insulin re‐
sistance and inadequate insulin secretion (Masharani, 2008). Type 1 diabetes is caused by ab‐
solute deficiency of insulin secretion. Individuals at risk of developing this type of diabetes
are found with serologic evidence of an autoimmune process occurring in the pancreatic is‐
lets and by genetic markers. In type 2 diabetes, it is a combination of resistance to insulin
action and an inadequate compensatory insulin secretion response (American Diabetes As‐
sociation, 2008). Diabetic nephropathy, one of the common complications of diabetes, has
become the leading cause of end-stage renal failure in many countries (Chen et al., 2005). In
general, about 1 out of 3 patients with type 1 or type 2 diabetes proceed to developing sig‐
nificant diabetic nephropathy (Zipp and Schelling, 2003). It is believed that the pathophysio‐
logic mechanisms of renal disorder are similar in both types of diabetes (Kern et al., 1999).
The pathogenesis and clinical course of diabetic nephropathy can be monitored by structural
and hemodynamic changes. The earliest changes is an increase in glomerular filtration rate
(GFR), also call “hyperfiltration” stage, which is followed by detectable glomerular lesions
with normal albumin excretion rate. The next change is the development of microalbuminu‐
ria. Once microalbuminuria persist, both changes in glomerular structure, such as mesangial
expansion and basement membrane thickening, and permeability happened, which is refer‐
red as “incipient nephropathy”. Diabetic subjects with persistent microalbuminuria are at
increased risk for “overt diabetic nephropathy”. At this stage, prominent proteinuria, hyper‐
tension, and renal insufficiency progressed. The pathological findings in this stage are glo‐
merular basement membrane (GBM) thickening, mesangial expansion and resulting in
diffuse and/or nodular glomerulosclerosis, afferent and efferent arteriolar hyalinosis, and tu‐
bulointerstitial fibrosis (Cooper and Gilbert, 2003). After several years of persistent proteinu‐
ria, progression to end-stage renal disease will occur (Caramori and Mauer, 2001).
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Advanced diabetic glomerulopathy is commonly characterized by diffuse glomerulosclero‐
sis and may sometimes exhibit a distinctive morphological appearance, namely, the nodular
form of glomerulosclerosis, as first described by Kimmelstiel and Wilson in 1936 (Kimmel‐
stiel and Wilson, 1936; Kern et al., 1999). The stages of diabetic nephropathy are shown in
Table 1 (Vora and Ibrahim, 2003).
Stage Renal manifestation
1 Renal hyperfiltration (GFR↑)
Renal hypertrophy
2 Silent stage
Renal hyperfiltration (GFR*↑); Normal UAER*, blood pressure
Early histologic changes: non-specific increase in basement membrane thickness, increase
mesangial matrix
3 Microalbuminuria (UAER 30-300mg/24 h) or incipient nephropathy
GFR may elevated or reduced into normal range.
Histology: mesangial expansion, glomerular basement membrane thickening, arteriolar hyalinosis
4 Established or overt nephropathy (Proteinuria, nephrotic syndrome)
GFR decline, Hypertension
Histology: mesangial nodules (Kimmelstiel-Wilson lesions), tubulointerstitial fibrosis
5 ESRD***
* GFR, glomerular filtration rate
**UAER, urine albumin excretion rate
***ESRD, end stage renal disease
Table 1. Natural course of diabetic nephropathy in type 1 diabetes
The current strategies to treat diabetic nephropathy include intensive glycemic control, anti‐
hypertensive treatment with a particular focus on the interruption of renin-angiotensin-al‐
dosterone system (RAS), restriction of dietary protein, and treatment of hyperlipidemia.
There are several new approaches to the treatment of diabetic nephropathy based on an ev‐
er-growing mechanistic understanding of the causes of diabetic nephropathy by the specific
pathogenic roles. These agents include pharmacologic inhibitors of advanced glycation end
products (AGEs) formation, protein kinase C (PKC), oxidative stress, and transforming
growth factor β (TGF-β) (Williams and Stanton, 2005).
2. Animal models of diabetes mellitus
Type 1 diabetes mellitus is typically an immune mediated destruction of the pancreatic
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β cells. Type 2 diabetes mellitus is characterized by insulin resistance and insulin secretion
impairment. Animal models have been used extensively in the field of diabetes study. The
current available animal models of type 1 and type 2 diabetes are shown in Table 2 (Rees
and Alcolado, 2005).
Type 1 BB (Bio breeding) rat
Chinese hamster
Celebes black ape
Keeshond dog
LETL (Long Evans Tokushima lean) rat
New Zeland white rabbit
NOD (non-obese diabetic) mouse
Streptozotocin-induced rats
Type 2 CBA/Ca mouse
db/db mouse
Diabetic Torri rat
GK (GotoKakizaki) rat
Israeli sand rat
KK mouse
New Zeland obese mouse
NSY (Nagoya-Shibata-Yasuda) mouse
Ob/Ob mouse
OLETF (Otsuka Long-Evans Tokushima fatty) rat
Zucker rat
Table 2. Animal models of type 1 and 2 diabetes mellitus
3. The molecular mechanism of oxidative stress in diabetic nephropathy
There are four major biochemical pathways considered to lead to the development of diabet‐
ic complications associated with hyperglycemia, (1) the polyol pathway, glucose is convert‐
ed to sorbitol and then metabolized to fructose. Advanced glycation end products (AGE)
and reactive oxygen species (ROS) formation also occurs via this pathway, (2) the hexosa‐
mine pathway, fructose-6-phosphate is converted to glucosamine intermediates and the pro‐
duction of ROS is subsequently increased, (3) the protein kinase C (PKC) pathway, glucose
is converted to glyceraldehyde-3-phosphate and leads to the formation of diacylglycerol
(DAG). The elevation of intracellular DAG levels activate PKC, and then activate NADPH
oxidase to induce ROS, (4) the formation of advanced glycation end products (AGEs), inter‐
action of AGEs with the receptors of advanced glycation end-products (RAGE) results in
ROS activation (Stirban et al., 2008; Shah et al., 2009; Forbes et al., 2008; Brownlee, 2005; Kan‐
war et al., 2008; Singh et al., 2011).
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Increased oxidative stress has been a widely accepted participant in the development and
progression of diabetes and its complications (Maritim et al.,  2003). ROS are activated in
glomerular  mesangial  and  tubular  epithelial  cells  by  high  glucose,  AGE,  and  cytokines
(Park et al., 1999). Hyperglycemia activates the glycolytic pathway and excess generation
of mitochondrial ROS initiates a vicious circle by activating several signaling to increase
protein kinase C (PKC), and stimulating NADPH oxidase to induce ROS generation (Jo‐
hansen  et  al.,  2005).  Free  radicals  has  been  found  to  be  formed  disproportionately  in‐
crease in  diabetic  subjects  by glucose oxidation,  nonenzymaticglycation of  proteins,  and
then oxidative  degradation of  glycated proteins.  Excessively  amount  of  free  radicals  in‐
duce  damage  to  cellular  proteins,  membrane  lipids,  nucleic  acids,  and  then  cell  death
(Maritim et al., 2003). Besides, increased ROS can cause vascular endothelium abnormali‐
ties,  reacting  directly  with  nitric  oxide  (NO)  to  produce  cytotoxic  peroxynitrite  and  in‐
creasing  reactivity  to  vasoconstrictors  and  modification  of  extracellular  matrix  proteins
(Schnackenberg,  2002).  ROS can  also  damage  endothelial  cells  indirectly  by  stimulating
expression of various genes involved in inflammatory pathway (Baldwin, 1996). Previous
study finds that high glucose induces ROS and then up-regulates TGF-β1 and extracellu‐
lar matrix (ECM) expression in the glomerular mesangial cell (Lee et al., 2003). There are
also evidences that antioxidants can effectively inhibit high glucose induced TGF-β1 and
fibronectin  up-regulation  (Ha  et  al.,  1997).  Ha  et  al.  (2002)  reported  that  ROS  mediate
high glucose-induced activation of  NF-κB and NF-κB dependent monocyte chemoattrac‐
tant  protein  (MCP)-1  expression.  NF-κB,  a  nuclear  transcription  factor,  can  initiate  the
transcription  of  genes  associated  with  inflammatory  response.  It  is  induced  by  various
cell  stress-associated  stimuli  including  growth factors,  vasoactive  agents,  cytokines,  and
oxidative stress (Kuhad and Chopra, 2009). Advanced glycation end products induced by
hyperglycemia stimulate NF-κB activation, which sustains the activation of NF-κB in dia‐
betes (Gao et al.,  2006). Increased steady-state mRNA levels of inflammatory genes have
been shown to associate with interstitial  fibrosis and progressive human diabetic nephr‐
opathy (Kuhad and Chopra, 2009).
TGF-β plays an important role in the development of  renal  hypertrophy and accumula‐
tion  of  extracellular  matrix  (ECM) components  in  diabetes  mellitus  (Wolf  and Ziyadeh,
1999).  The expression of  TGF-β was found increased in diabetic  nephropathy of  experi‐
mental  animals  and in humans (Park et  al.,  1997;  Yamamoto et  al.,  1993;  Sharma et  al.,
1997; Shankland et al.,  1994).  Treatment with anti-TGF-β antibody has been documented
that it  attenuated the effect of high glucose induced cellular hypertrophy in vitro  and in
streptozotocin-induced  diabetic  mice  (Wolf  et  al.,  1992;  Ziyadeh  et  al.,  1994;  Sharma  et
al., 1996). TGF-β is also the key regulator of ECM remodeling in mesangium causing me‐
sangial  expansion  and inducing  the  process  of  epithelial-mesenchymal  transition  (EMT)
causing tubulointerstitial fibrosis (Ziyadeh et al., 2000; Oldfield et al., 2001). As the accu‐
mulation of ECM and persistence of tubulointerstitial fibrosis, the renal function progress
to  end-stage  renal  disease  (ESRD).  The  relation  between  oxidative  stress  and  diabetic
nephropathy are shown in Figure 1 (Shah et al, 2007).
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Figure 1. The relation between oxidative stress and diabetic nephropathy* *PKC, protein kinase C; AGE, advanced gly‐
cation end products; ROS, reactive oxygen species; NF-κB, nulcear factor-kappa B; AP-1,activator protein-1; TGF-β,
transforming growth factor-beta; MCP-1, monocyte chemotactic protein-1
4. Improvement of antioxidantive status in diabetic nephropathy
There are many evidences suggest that ROS play an important role in the pathogenesis of
diabetic nephropathy (Rosen et al., 2001). To prevent the development and progression of
diabetic nephropathy, it would be effective in combing the strategies to prevent overproduc‐
tion of ROS and to increase the removal of preformed ROS. (Ha et al., 2008). Some natural
products were proved to possess the ability to decelerate diabetic nephropathy via reducing
oxidative status. The flower of Hibiscus sabdariffaLinnaeus calyx (family Malvaceae, local
name Karkaday) is commonly used in cold and hot beverages and as a supplement due to
its perceived potential of health benefits. The flower extract has been reported to decrease
blood pressure, and have antitumor characteristics as well as immune-modulating and anti‐
leukemic effects (Haji Faraji and Haji Tarkhani, 1999; Tseng et al., 2000). Hibiscus sabdariffaL.
extract contains polyphenolic acids, flavonoids, protocatechuic acid (PCA) and anthocya‐
nins. Hibiscus sabdariffaL. extract has been found to contain various polyphenols and was
shown to have antioxidative potential to inhibit the development of atherosclerosis in cho‐
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lesterol-fed rabbits, LDL oxidation and ox-LDL-mediated macrophage apoptosis (Chen et
al., 2003; Chang et al., 2006). Wang et al. (2009) demonstrated that aqueous extract of Hibis‐
cus sabdariffa L. (HSE) is capable of increasing catalase and glutathione activities significantly
in diabetic kidney. In histological examination, HSE improves hydropic change of renal
proximal convoluted tubules in diabetic rats. HSE was also revealed to up-regulate Akt/Bad/
14-3-3฀ and NF-κB-mediated transcription in diabetic nephropathy. Luteolin is a plant-de‐
rived flavonoid, it has various biological activities including anti-inflammatory (Jang et al.,
2008), antimutagenic, and antitumorigenic properties (Ross and Kasum, 2002). It also pos‐
sesses direct antioxidant activity (L´opez-L´azaro, 2009), and may be useful in treatment of
many chronic disease associated with oxidative stress, such as cardiovascular diseases
(McCord, 1985; Jeroudi et al., 1994), liver diseases (Comporti, 1985; Poli et al., 1987), diabetes
(Oberley, 1988), and aging (Harman, 1981). Wang et al. (2011) demonstrated that luteolin
has protecting effect against development of diabetic nephropathy by changing the superox‐
ide dismutase (SOD) activity, the malondialdehyde (MDA) content, and expression of Heme
Oxygenase-1 (HO-1) protein.
On the other hand, some evidences show the exogenous or endogenous antioxidants also
can reduce diabetic nephropathy. Oxidative stress via nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase and vascular endothelial growth factor (VEGF) pathway are
documented to play important roles in the development of diabetic nephropathy. Nam et al.
(2009) showed the effects of apocynin, a NADPH oxidase inhibitor, on diabetic nephrop‐
athy. They found that apocynincan not significantly decrease serum glucose levels but re‐
duce urinary protein and albumin excretions. It is improved in glomerular and mesangial
expansion as the apocynin treatment. Apocynin also decreased glomerular VEGF expression
and reduced the concentration of 24 h urinary 8-OHdG and MDA. Additionally, Lee et al.
(2005) demonstrated that antioxidant taurine prevented glomerular hypertrophy, mesangial
expansion, and proteinuria in diabetic rats. Overexpression of catalytic antioxidants was al‐
so shown to protect against diabetic injury in several transgenic animals. Craven et al. (2001)
showed that diabetic mice transgenic for Cu/Zn SOD had significantly lower urinary albu‐
min excretion, glomerular hypertrophy, and glomerular expression of TGF-β1 and collagen
IV protein compared to non-transgenic mice. Hamada et al. (2007) demonstrated that over‐
expression a small antioxidant, thioredoxin 1, effectively inhibited 8-OHdG in the kidney,
albuminuria, mesangial expansion, and tubular injury in diabetic mice. Du et al. (2003)
found that overexpression of MnSOD in bovine aortic endothelial cells prevented high glu‐
cose-induced activation of PKC, NK-kB, hexosamine, and advanced glycation end product
(AGE) pathways. Brezniceanu et al. (2007) demonstrated that renal catalase overexpression
in db/db mice attenuated ROS generation, angiotensinogen, proapoptotic gene expression
and apoptosis in the kidneys of diabetic mice in vivo.
Although strict glycemic control is very important in DM patients, many of the current
standard therapeutic approaches may also ameliorate oxidative stress as pleiotropic effects
(Singh et al., 2011), such as angiotensin-2 converting enzyme (ACE) inhibitors(Kobayashi et
al., 2006), angiotensin-2 receptor blockers (ARB) (Ogawa et al., 2006) and aldosterone block‐
ers (spironolactone) (Takebayashi et al., 2006). They activate eNOS to increase bioavailability
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of nitric oxide, inhibit synthesis of angiotensin 2 and TGF-β and to decelerate or prevent tu‐
bulointerstitial fibrosis in diabetic nephropathy, accompanied with control of systemic and
intrarenal blood pressure. Cilostazol is a specific inhibitor of phosphodiesterase 3 (PDE 3).
Its major effects are prevention of platelet aggregation and dilation of blood vessels via an
increase in tissue cAMP levels (Matsumoto et al., 2005). Cilostazol was shown to inhibit vas‐
cular smooth muscle cell proliferation in vitro as well as suppress neointimal formation in
balloon-injured rat carotid arteries due to its antiplatelet and vasodilator properties (Takaha‐
shi et al., 1992; Ishizaka et al., 1999). Our previous study showed that cilostazol decreases
reactive oxygen species activity significantly in the kidneys of diabetic rats and improves
urine albumin/creatinine ratio. Cilostazol also can improve the diabetes-caused increasing
glomerular size, TGF-β, and NF-kB in early diabetic nephropathy (Lee et al., 2010). The lip‐
id-lowering agents such as statins, which can inhibit HMG-CoA reductase to be demonstrat‐
ed to activate eNOS, maintain glomerular filtration rate and renal cortical blood flow, and
further to ameliorate glomerular lesions(Usui et al., 2003; Endres and Laufs, 2004). Benfotia‐
mine was used in the treatment of diabetic nephropathy, it was also demonstrated to reduce
ROS formation and may decrease hyperfiltration and proteinuria in patients with diabetic
nephropathy(Babaei-Jadidi et al., 2003). Potential therapies in these ideal antioxidants would
influence the pathways of ROS generation to decelerate diabetic nephropathy.
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